FluBuATG
Phase 1 Completed
20 enrolled
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Phase 3 Completed
101 enrolled 28 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Phase 2 Completed
62 enrolled 15 charts
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
14 enrolled
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
140 enrolled
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Phase NA Completed
18 enrolled 7 charts
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Phase 1 Completed
11 enrolled
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Phase 2 Completed
20 enrolled 10 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
LCCC0510
Phase 1/2 Completed
54 enrolled 17 charts
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase 2 Completed
71 enrolled 12 charts
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
MINI HEME
Phase 2 Completed
25 enrolled
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Phase 1 Completed
5 enrolled
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2 Completed
60 enrolled
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Phase 2 Completed
82 enrolled
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase 2 Completed
32 enrolled 24 charts
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
Phase 2 Completed
40 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
Phase 2 Completed
20 enrolled
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
Phase NA Completed
25 enrolled
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
Phase 2 Completed
20 enrolled
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Phase 2 Completed
13 enrolled